Metabolic / Weight Management
Survodutide
Dual GLP-1/glucagon receptor agonist. Phase 3 SYNCHRONIZE-1: 16.6% weight loss.
Evidence: 3 articles
Goals: 1
Mechanism of Action
Bioregulator compound with targeted biochemical activity.
Evidence Level
Clinical Trial - Human
3 studies published
Pharmacology
Molecular Weight
~3,970 Da (with fatty acid side chain)
Half-Life
~130–165 hours (enabling once-weekly dosing)
Bioavailability
Subcutaneous injection; albumin-binding via acyl side chain extends systemic exposure